ClinicalTrials.gg
CompletedNCT01999894Updated Mar 18, 2014Results posted

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

A Phase 2 interventional study of Memantine HCl in Autism and Pediatric Autism, sponsored by Forest Laboratories. Completed at 19 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2014-03-18.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
119th of 504
102 · median 44
Started
2009
with 27 others
Phase 2
95 of 603
11 open now
Registered
244th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 119th largest by enrollment of the 504 interventional ones that give a count, is one of 28 that started in 2009, is one of 95 in phase 2, and was the 244th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.

Read the detailed description

This is a 48-week multicenter extension study comprised of a 6-week double-blind dose-titration period followed by a 42-week open-label maintenance period.

In the Forest autism trials conducted in children ages 6-12, dosing with an extended release formulation of memantine was weight-based. These weight based dose limits were selected to ensure exposure in terms of area under the curve (AUC) was less than the predefined limit of 2100 ng∙h/mL that represented a 10-fold lower exposure than observed at the NOAEL (No observed adverse effect level) of 15 mg/kg/day in juvenile rats.

The weight-based dose limits in these studies were as follows:

  • Group A: ≥ 60 kg; max 15 mg/day
  • Group B: 40-59 kg; max 9 mg/day
  • Group C: 20-39 kg; max 6 mg/day
  • Group D: \< 20 kg; max 3 mg/day
03

Conditions studied

  • Autism
  • Pediatric Autism

Browse trials for

Keywords

  • Namenda
  • Autism
  • Memantine
  • Pediatric
  • Forest Laboratories
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed lead-in study MEM-MD-57A (NCT00872898)
  • A knowledgeable caregiver capable of providing reliable information about the patient's condition, able to attend all clinic visits with the patient

Exclusion criteria

Exclusion Criteria:

  • Patients with a concurrent medical condition that might interfere with the conduct of the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Memantine

    Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.

    Drug: Memantine HCl

Interventions

  • Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.

    Also known as: Namenda, Namenda XR

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)

    Number of patients who experienced one or more TEAEs during the study

    Time frame: From Visit 1 (Week 1) to 30 days after Visit 8 (Week 48)

07

Results

Posted Mar 18, 2014

Participant flow

Patients who completed the lead-in study MEM-MD-57A (NCT00872898) were eligible to enroll in this study. A total of 19 study centers in the United States enrolled patients.

Participant flow — Overall Study
MilestoneMemantine
Started102
Completed66
Not completed36
Withdrew: Adverse event9
Withdrew: Lack of efficacy5
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up10
Withdrew: Other reason3
Withdrew: Inclusion/exclusion criteria not met1

Outcome measures

PrimaryNumber of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)

Number of patients who experienced one or more TEAEs during the study

Time frame:
From Visit 1 (Week 1) to 30 days after Visit 8 (Week 48)
Reported as:
Number · participants
Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)
participantsMemantine
Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)85

Adverse events

Collected over Adverse event data was collected over a 40 month period from November 2009 to March 2013 at 19 study sites in the US.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo to Memantine—1/50 (2%)37/50 (74%)
Memantine to Memantine—0/52 (0%)37/52 (71.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo to MemantineMemantine to Memantine
Lobar pneumoniaInfections and infestations1/500/52
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlacebo to MemantineMemantine to Memantine
Upper respiratory tract infectionInfections and infestations5/5010/52
Seasonal allergyImmune system disorders7/502/52
VomitingGastrointestinal disorders6/502/52
ConstipationGastrointestinal disorders5/502/52
Weight increasedInvestigations5/504/52
AggressionPsychiatric disorders5/503/52
InsomniaPsychiatric disorders5/503/52
CoughRespiratory, thoracic and mediastinal disorders5/505/52
Nasal congestionRespiratory, thoracic and mediastinal disorders5/503/52
IrritabilityGeneral disorders2/505/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Memantine
Years9.1 ± 2.2
Sex: Female, Male
Sex: Female, Male(Participants)Memantine
Female15
Male87
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Memantine
White86
Black2
Asian9
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander1
Other4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Memantine
Hispanic or Latino11
Non-Hispanic or Latino91
Region of Enrollment
Region of Enrollment(participants)Memantine
United States102
08

Study locations

19 sites
  • Forest Investigative Site 005
    Phoenix, Arizona 85006, United States
  • Forest Investigative Site 003
    Sacramento, California 95817, United States
  • Forest Investigative Site 021
    San Francisco, California 94143, United States
  • Forest Investigative Site 026
    Santa Ana, California 92701, United States
  • Forest Investigative Site 020
    Santa Ana, California 92705, United States
  • Forest Investigative Site 002
    Stanford, California 94305, United States
  • Forest Investigative Site 024
    Jacksonville Beach, Florida 32250, United States
  • Forest Investigative Site 007
    St. Petersburg, Florida 33701, United States
  • Forest Investigative Site 014
    Hoffman Estates, Illinois 60169, United States
  • Forest Investigative Site 023
    Naperville, Illinois 60563, United States
  • Forest Investigative Site 010
    Indianapolis, Indiana 46202, United States
  • Forest Investigative Site 025
    Cambridge, Massachusetts 02138, United States
  • Forest Investigative Site 011
    Toms River, New Jersey 08755, United States
  • Forest Investigative Site 006
    Voorhees, New Jersey 08043, United States
  • Forest Investigative Site 017
    Manhasset, New York 10030, United States
  • Forest Investigative Site 013
    Cleveland, Ohio 44106, United States
  • Forest Investigative Site 015
    Cleveland, Ohio 44106, United States
  • Forest Investigative Site 001
    Columbus, Ohio 43210, United States
  • Forest Investigative Site 019
    Oklahoma, Oklahoma 73116, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
Start
Nov 2009
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Mar 18, 2014
Last update
Mar 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01999894
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Nov 2009
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Mar 18, 2014
Last update
Mar 18, 2014

Study contacts

Ephraim Katz, PhD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion